Float Short %

10.52

Margin Of Safety %

Put/Call OI Ratio

0.87

EPS Next Q Diff

0.3

EPS Last/This Y

-0.75

EPS This/Next Y

-1.04

Price

1.76

Target Price

4.2

Analyst Recom

2.57

Performance Q

-21.59

Relative Volume

2.91

Beta

1.63

Ticker: MGNX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	MGNX	1.535	1.10	0.00	2170
2025-05-09	MGNX	1.425	1.10	0.00	2170
2025-05-12	MGNX	1.59	1.08	0.00	2198
2025-05-13	MGNX	1.56	1.07	0.95	2211
2025-05-14	MGNX	1.555	1.06	0.40	2242
2025-05-15	MGNX	1.54	1.04	1.25	2281
2025-05-16	MGNX	1.58	1.03	0.00	2286
2025-05-19	MGNX	1.59	0.92	0.00	2085
2025-05-20	MGNX	1.56	0.91	1.50	2097
2025-05-21	MGNX	1.485	0.91	1.50	2097
2025-05-22	MGNX	1.575	0.90	0.00	2095
2025-05-23	MGNX	1.51	0.90	0.00	2100
2025-05-27	MGNX	1.48	0.88	0.22	2115
2025-05-28	MGNX	1.39	0.88	0.22	2115
2025-05-29	MGNX	1.395	0.88	0.22	2115
2025-05-30	MGNX	1.36	0.88	0.00	2118
2025-06-02	MGNX	1.39	0.88	0.00	2124
2025-06-03	MGNX	1.515	0.88	0.00	2125
2025-06-04	MGNX	1.495	0.87	0.00	2126
2025-06-05	MGNX	1.445	0.86	999.99	2146
2025-06-06	MGNX	1.765	0.87	0.00	2156
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	MGNX	1.53	17.9	-	-2.89
2025-05-09	MGNX	1.43	17.9	-	-2.89
2025-05-12	MGNX	1.59	17.9	-	-2.89
2025-05-13	MGNX	1.54	17.9	-	-2.89
2025-05-14	MGNX	1.55	17.9	-	-2.89
2025-05-15	MGNX	1.54	17.9	-	-2.89
2025-05-16	MGNX	1.59	17.9	-	-2.89
2025-05-19	MGNX	1.59	15.7	-	-2.15
2025-05-20	MGNX	1.57	15.4	-	-2.15
2025-05-21	MGNX	1.47	15.4	-	-2.15
2025-05-22	MGNX	1.58	15.4	-	-2.15
2025-05-23	MGNX	1.51	15.4	-	-2.15
2025-05-27	MGNX	1.49	15.4	-	-2.15
2025-05-28	MGNX	1.39	15.4	-	-2.15
2025-05-29	MGNX	1.40	15.4	-	-2.15
2025-05-30	MGNX	1.36	15.4	-	-2.15
2025-06-02	MGNX	1.39	25.8	-	-1.82
2025-06-03	MGNX	1.51	25.8	-	-1.82
2025-06-04	MGNX	1.50	25.8	-	-1.82
2025-06-05	MGNX	1.45	25.8	-	-1.82
2025-06-06	MGNX	1.76	25.8	-	-1.82
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	MGNX	-0.01	-0.95	9.20
2025-05-09	MGNX	-0.01	-0.95	9.20
2025-05-12	MGNX	-0.01	-0.22	9.79
2025-05-13	MGNX	-0.01	-0.22	9.79
2025-05-14	MGNX	-0.01	-0.22	9.79
2025-05-15	MGNX	-0.01	-0.22	9.82
2025-05-16	MGNX	-0.01	-0.22	9.82
2025-05-19	MGNX	-0.01	0.36	9.79
2025-05-20	MGNX	-0.01	0.36	9.79
2025-05-21	MGNX	-0.01	0.36	9.79
2025-05-22	MGNX	-0.01	0.36	9.79
2025-05-23	MGNX	-0.01	0.36	9.79
2025-05-27	MGNX	-0.01	-7.58	9.80
2025-05-28	MGNX	-0.01	-7.58	10.52
2025-05-29	MGNX	-0.01	-7.58	10.52
2025-05-30	MGNX	-0.01	-7.58	10.52
2025-06-02	MGNX	-0.01	-5.12	10.52
2025-06-03	MGNX	-0.01	-5.12	10.52
2025-06-04	MGNX	-0.01	-5.12	10.52
2025-06-05	MGNX	-0.01	-5.12	10.52
2025-06-06	MGNX	-0.01	-5.12	10.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.65

Avg. EPS Est. Current Quarter

-0.66

Avg. EPS Est. Next Quarter

-0.35

Insider Transactions

-0.01

Institutional Transactions

-5.12

Beta

1.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.2

Max Drawdown 5-Year %

-97

Target Price

4.2

P/E

Forward P/E

PEG

P/S

0.73

P/B

1.42

P/Free Cash Flow

EPS

-0.89

Average EPS Est. Cur. Y

-1.82

EPS Next Y. (Est.)

-2.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-36.23

Relative Volume

2.91

Return on Equity vs Sector %

-94.6

Return on Equity vs Industry %

-76.6

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

1.07

EBIT Estimation

MacroGenics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 341

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

stock quote shares MGNX – Macrogenics Inc Stock Price stock today

news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MGNX – Macrogenics Inc yahoo finance google finance

stock history MGNX – Macrogenics Inc invest stock market

stock prices MGNX premarket after hours

ticker MGNX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MGNX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y